Gene editing exploits DNA-binding sequence-specific nucleases to precisely and permanently modify the targeted genome. Currently, the most widely used genome editing tools is the CRISPR/Cas-based technology. CRISPR/Cas-based system is an easy-to-use genome editing tool, as efficient DNA manipulation only requires a small RNA molecule targeting the sequence of interest. Since their original discovery, a wide variety of CRISPR/Cas tools have been developed in order to tackle different genome architectures and scientific questions. Very recently, FDA approved the first Gene Therapy utilizing CRISPR/Cas technology to treat patients with sickle cell disease. Despite the tremendous advancement in the clinical application of CRISPR/Cas system, a side-by-side evaluation of the developed tools are still lacking in the field.
The goal of this Research Topic collection is to provide a comprehensive overview of the current developed CRISPR/Cas-based genome editing tools and their application in the field of gene therapy, cancer gene therapy and cancer immunotherapy.
The areas covered by this research topic include, but are not limited to:
- side-by-side comparison of safety and efficacy of different CRISPR/Cas-based genome editing tools;
- methods to assess on-target efficacy and off-target frequencies;
- strategies for efficient CRISPR/Cas delivery;
- therapeutic application of CRISPR/Cas-based genome editing tools, with a focus on safety and efficacy evaluations;
- application of CRISPR/Cas-based tools for the development and investigation of disease models
This research topic welcomes original research articles, reviews, and perspectives.
Dr. Beatrice Cianciotti is an inventor in a patent related to cancer immunotherapy and genetic engineering.
Dr. Samuele Ferrari is an inventor in patents related to gene editing in hematopoietic cells.
Dr. Karl Petri has a financial interest in SeQure Dx.
Keywords:
CRISPR/Cas; genome editing; on-target; off-targets; delivery;
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Gene editing exploits DNA-binding sequence-specific nucleases to precisely and permanently modify the targeted genome. Currently, the most widely used genome editing tools is the CRISPR/Cas-based technology. CRISPR/Cas-based system is an easy-to-use genome editing tool, as efficient DNA manipulation only requires a small RNA molecule targeting the sequence of interest. Since their original discovery, a wide variety of CRISPR/Cas tools have been developed in order to tackle different genome architectures and scientific questions. Very recently, FDA approved the first Gene Therapy utilizing CRISPR/Cas technology to treat patients with sickle cell disease. Despite the tremendous advancement in the clinical application of CRISPR/Cas system, a side-by-side evaluation of the developed tools are still lacking in the field.
The goal of this Research Topic collection is to provide a comprehensive overview of the current developed CRISPR/Cas-based genome editing tools and their application in the field of gene therapy, cancer gene therapy and cancer immunotherapy.
The areas covered by this research topic include, but are not limited to:
- side-by-side comparison of safety and efficacy of different CRISPR/Cas-based genome editing tools;
- methods to assess on-target efficacy and off-target frequencies;
- strategies for efficient CRISPR/Cas delivery;
- therapeutic application of CRISPR/Cas-based genome editing tools, with a focus on safety and efficacy evaluations;
- application of CRISPR/Cas-based tools for the development and investigation of disease models
This research topic welcomes original research articles, reviews, and perspectives.
Dr. Beatrice Cianciotti is an inventor in a patent related to cancer immunotherapy and genetic engineering.
Dr. Samuele Ferrari is an inventor in patents related to gene editing in hematopoietic cells.
Dr. Karl Petri has a financial interest in SeQure Dx.
Keywords:
CRISPR/Cas; genome editing; on-target; off-targets; delivery;
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.